Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

NCT02182206 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02182206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02182206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2003
Completion date
Not reported
Enrollment
50 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tumors